Norursodeoxycholic acid

Drug Profile

Norursodeoxycholic acid

Alternative Names: NorUDCA; Ursodeoxycholic acid homologue

Latest Information Update: 15 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dr Falk Pharma
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants
  • Mechanism of Action Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis

Most Recent Events

  • 07 Aug 2017 Dr. Falk Pharma plans a phase III trial for Primary sclerosing cholangitis in Austria (EudraCT2016-003367-19)
  • 16 Dec 2015 Phase-II development for Primary sclerosing cholangitis is ongoing in Austria, Belgium, Germany, Lithuania, Netherlands, Sweden, United Kingdom, Spain, Finland, Hungary, Denmark and Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top